The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preoperative radiotherapy for high-risk prostate cancer (PORT-PC) trial.
 
Himanshu Nagar
No Relationships to Disclose
 
Silvia Formenti
Honoraria - AstraZeneca; Bristol-Myers Squibb; Dynavax Technologies; Eisai; GlaxoSmithKline; Janssen; Merck; Regeneron; Varian Medical Systems
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; Merck
Speakers' Bureau - Varian Medical Systems
Research Funding - Bristol-Myers Squibb; Eisai; Janssen; Merck; Regeneron; Varian Medical Systems
Patents, Royalties, Other Intellectual Property - New York University, assignee, US patent 7,763,864
Travel, Accommodations, Expenses - AstraZeneca; Merck
 
Douglas Scherr
No Relationships to Disclose
 
Jim C. Hu
Speakers' Bureau - Genomic Health; Intuitive Surgical
Travel, Accommodations, Expenses - Intuitive Surgical
 
Peter Schlegel
No Relationships to Disclose
 
Josephine Kang
No Relationships to Disclose
 
Brian D. Robinson
Stock and Other Ownership Interests - Metastat
Consulting or Advisory Role - Progenics
Patents, Royalties, Other Intellectual Property - methods for diagnosing and treating prostate cancer
 
Francesca Khani
No Relationships to Disclose
 
David M. Nanus
Consulting or Advisory Role - Roche/Genentech
 
Scott T. Tagawa
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bayer; Dendreon; Endocyte; Genentech; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Sanofi; Tolmar
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)
Travel, Accommodations, Expenses - Immunomedics; Sanofi
 
Ana M. Molina
Honoraria - ASCO
Consulting or Advisory Role - Eisai; Exelixis; Janssen; Novartis
 
Bishoy Morris Faltas
Honoraria - Digital Science Press
Research Funding - Lilly
 
Daniel Margolis
Honoraria - Hitachi
Consulting or Advisory Role - Blue Earth Diagnostics
Travel, Accommodations, Expenses - Hitachi
 
Christopher Barbieri
Patents, Royalties, Other Intellectual Property - A patent application has been filed regarding SPOP mutations in prostate cancer by Weill Cornell Medicine. I am a co-inventor.